Reports
As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
Global Haemoglobinopathies Market: By Type: Thalassemia, Sickle Cell Disease; By Test Type: Routine Red Blood Cell (RBC) Count, Genetic Testing; By End Use; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Value Chain Analysis; Manufacturing Process; Competitive Landscape; Industry Events and Developments
Global Haemoglobinopathies Market Outlook
The global haemoglobinopathies market is expected to grow at a CAGR of 7.8% in the forecast period of 2022-2027.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The Asia Pacific is Expected to Provide Enhanced Growth Opportunities for the Haemoglobinopathies Industry
North America significantly contributes to the growth of the industry owing to the presence of advanced healthcare facilities, better reimbursement policies, and growing R&D activities in the region. The growing prevalence of haemoglobinopathies in European countries, particularly Germany, is also contributing to the industry growth. Meanwhile, the Asia Pacific is expected to witness a healthy growth over the forecast period owing to the unmet needs of the patients suffering from haemoglobinopathies. The growing awareness regarding haemoglobinopathies, improving healthcare infrastructures, and favourable government initiatives are propelling the market growth in the Asia Pacific.
Haemoglobinopathies: Industry Definition and Segmentation
Haemoglobinopathies refer to a group of genetic disorders that affect red blood cells or the structure or production of the haemoglobin molecule. Encompassing all genetic diseases of haemoglobin, hemoglobinopathies are the most common monogenic diseases. They fall into two main groups, namely, thalassemia syndromes and structural haemoglobin variants (abnormal haemoglobins). The clinical manifestations of these disorders are highly variable and can range from mild hypochromic anaemia to moderate haematological disease to severe, lifelong, transfusion-dependent anaemia having multiorgan involvement.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on type, the market is divided into:
- Thalassemia
- Sickle Cell Disease
- Others
Among these, the thalassemia segment is further bifurcated into alpha thalassemia and beta thalassemia on the basis of type
On the basis of test type, the industry can be segmented into:
- Routine Red Blood Cell (RBC) Count
- Genetic Testing
- Haemoglobin by High Performance Liquid Chromatography
- Haemoglobin Isoelectric Focusing (Hb IEF)
- Haemoglobin Electrophoresis (Hb ELP)
- Haemoglobin Solubility Test
- Others
Based on end use, the industry can be categorised into:
- Hospitals
- Diagnostics Laboratories
- Clinics
- Others
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Growing Prevalence of Haemoglobinopathies and Increasing Diagnostic Facilities to Bolster the Haemoglobinopathies Industry Growth
The rising incidences of haemoglobinopathies across the globe and the increasing health awareness are driving the growth of the global market for haemoglobinopathies. The market is being supported by the favourable government initiatives to create awareness regarding haemoglobinopathies and the presence of improved diagnostic facilities, particularly in developing nations. Other factors like the growing adoption of Big Data and AI in the healthcare sector, growing focus on patient care, and growing healthcare infrastructures are further propelling the market growth. Over the forecast period, the growing R&D activities are expected to have a positive effect on the expansion of the global haemoglobinopathies industry.
Key Industry Players in the Global Haemoglobinopathies Market
The report gives a detailed analysis of the following key players in the global haemoglobinopathies market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Sanofi
- Bluebird Bio, Inc.
- Emmaus Medical, Inc.
- Prolong Pharmaceuticals, LLC.
- Global Blood Therapeutics, Inc.
- Others
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Test Type, End Use, Region |
| Breakup by Type | Thalassemia, Sickle Cell Disease, Others |
| Breakup by Test Type | Routine Red Blood Cell (RBC) Count, Genetic Testing, Haemoglobin by High Performance Liquid Chromatography, Haemoglobin Isoelectric Focusing (Hb IEF), Haemoglobin Electrophoresis (Hb ELP), Haemoglobin Solubility Test, Others |
| Breakup by End Use | Hospitals, Diagnostics Laboratories, Clinics, Others |
| Breakup by Region | North America, Latin America, Europe, Middle East and Africa, Asia Pacific |
| Market Dynamics | SWOT, Porter's Five Forces, EMR’s Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Sanofi, Bluebird Bio, Inc., Emmaus Medical, Inc., Prolong Pharmaceuticals, LLC., Global Blood Therapeutics, Inc., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Haemoglobinopathies Market Analysis
8.1 Key Industry Highlights
8.2 Global Haemoglobinopathies Historical Market (2017-2021)
8.3 Global Haemoglobinopathies Market Forecast (2022-2027)
8.4 Global Haemoglobinopathies Market by Type
8.4.1 Thalassemia
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.1.4 Breakup by Type
8.4.1.4.1 Alpha Thalassemia
8.4.1.4.1.1 Market Share
8.4.1.4.1.2 Historical Trend (2017-2021)
8.4.1.4.1.3 Forecast Trend (2022-2027)
8.4.1.4.2 Beta Thalassemia
8.4.1.4.2.1 Market Share
8.4.1.4.2.2 Historical Trend (2017-2021)
8.4.1.4.2.3 Forecast Trend (2022-2027)
8.4.2 Sickle Cell Disease
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Others
8.5 Global Haemoglobinopathies Market by Test Type
8.5.1 Routine Red Blood Cell (RBC) Count
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Genetic Testing
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Haemoglobin by High Performance Liquid Chromatography
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2017-2021)
8.5.3.3 Forecast Trend (2022-2027)
8.5.4 Haemoglobin Isoelectric Focusing (Hb IEF)
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2017-2021)
8.5.4.3 Forecast Trend (2022-2027)
8.5.5 Haemoglobin Electrophoresis (Hb ELP)
8.5.5.1 Market Share
8.5.5.2 Historical Trend (2017-2021)
8.5.5.3 Forecast Trend (2022-2027)
8.5.6 Haemoglobin Solubility Test
8.5.6.1 Market Share
8.5.6.2 Historical Trend (2017-2021)
8.5.6.3 Forecast Trend (2022-2027)
8.5.7 Others
8.6 Global Haemoglobinopathies Market by End Use
8.6.1 Hospitals
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Diagnostics Laboratories
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.6.3 Clinics
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2017-2021)
8.6.3.3 Forecast Trend (2022-2027)
8.6.4 Others
8.7 Global Haemoglobinopathies Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 EMR’s Key Indicators for Demand
10.4 EMR’s Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 Sanofi
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Bluebird Bio, Inc.
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Emmaus Medical, Inc.
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Prolong Pharmaceuticals, LLC.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Global Blood Therapeutics, Inc.
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Others
13 Industry Events and Developments
List of Figures and Tables
1. Global Haemoglobinopathies Market: Key Industry Highlights, 2016 and 2026
2. Global Haemoglobinopathies Historical Market: Breakup by Form (USD Million), 2017-2021
3. Global Haemoglobinopathies Market Forecast: Breakup by Form (USD Million), 2022-2027
4. Global Haemoglobinopathies Historical Market: Breakup by Application (USD Million), 2017-2021
5. Global Haemoglobinopathies Market Forecast: Breakup by Application (USD Million), 2022-2027
6. Global Haemoglobinopathies Historical Market: Breakup by Region (USD Million), 2017-2021
7. Global Haemoglobinopathies Market Forecast: Breakup by Region (USD Million), 2022-2027
8. North America Haemoglobinopathies Historical Market: Breakup by Country (USD Million), 2017-2021
9. North America Haemoglobinopathies Market Forecast: Breakup by Country (USD Million), 2022-2027
10. Europe Haemoglobinopathies Historical Market: Breakup by Country (USD Million), 2017-2021
11. Europe Haemoglobinopathies Market Forecast: Breakup by Country (USD Million), 2022-2027
12. Asia Pacific Haemoglobinopathies Historical Market: Breakup by Country (USD Million), 2017-2021
13. Asia Pacific Haemoglobinopathies Market Forecast: Breakup by Country (USD Million), 2022-2027
14. Latin America Haemoglobinopathies Historical Market: Breakup by Country (USD Million), 2017-2021
15. Latin America Haemoglobinopathies Market Forecast: Breakup by Country (USD Million), 2022-2027
16. Middle East and Africa Haemoglobinopathies Historical Market: Breakup by Country (USD Million), 2017-2021
17. Middle East and Africa Haemoglobinopathies Market Forecast: Breakup by Country (USD Million), 2022-2027
18. Global Haemoglobinopathies Market Structure
Key Questions Answered in the Report
The global haemoglobinopathies market is projected to grow at a CAGR of 7.8% between 2021 and 2026.
The major drivers of the industry, such as the increasing health awareness, growing prevalence of haemoglobinopathies, favourable government initiatives, and advancements in medical sector, are expected to aid the market growth.
The key market trends guiding the growth of the industry include the growing R&D activities and the rapid technological advancements in the healthcare sector.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading types of haemoglobinopathies in the market are thalassemia and sickle cell disease, among others.
The major test types in the industry are routine red blood cell (RBC) count, genetic testing, haemoglobin by high performance liquid chromatography, haemoglobin isoelectric focusing (Hb IEF), haemoglobin electrophoresis (Hb ELP), and haemoglobin solubility test, among others.
The significant end use sectors in the market are hospitals, diagnostics laboratories, and clinics, among others.
The major players in the industry are Sanofi, Bluebird Bio, Inc., Emmaus Medical, Inc., Prolong Pharmaceuticals, LLC., and Global Blood Therapeutics, Inc., among others.
Analyst Review
The global haemoglobinopathies market is being driven by the rising prevalence of haemoglobinopathies. Aided by the technological advancements, the market is expected to witness a healthy growth in the forecast period of 2022-2027, growing at a CAGR of 7.8%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. By type, the market is segmented into thalassemia and sickle cell disease, among others. Based on test type, the industry is divided into routine red blood cell (RBC) count, genetic testing, haemoglobin by high performance liquid chromatography, haemoglobin isoelectric focusing (Hb IEF), haemoglobin electrophoresis (Hb ELP), and haemoglobin solubility test, among others. On the basis of end use, the market is divided into hospitals, diagnostics laboratories, and clinics, among others. The major regional markets for haemoglobinopathies are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Sanofi, Bluebird Bio, Inc., Emmaus Medical, Inc., Prolong Pharmaceuticals, LLC., and Global Blood Therapeutics, Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?RIGHT PEOPLE
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
RIGHT METHODOLOGY
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
RIGHT PRICE
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
RIGHT SUPPORT
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global cell-based assays market reached a value of more than USD 6677 million in 2021, driven by the rising incidences of chronic illnesses, such as cancer and cardiovascular diseases. Aided by th...
The United States medical writing market attained a value of USD 0.9 billion in 2021, driven by the thriving healthcare and pharmaceutical industry in the country. Aided by the growing FDA approval of...
The global 3D printing in healthcare market attained a value of USD 1120.5 million in 2021, driven by the increased demand for 3D printing across the medical sector. Aided by heightened technological ...
The global sperm bank market attained a value of USD 4.62 billion in 2021, driven by the rising prevalence of various infertility and artificial insemination techniques. Aided by the growing technolog...
The global medical adhesives market attained a value of USD 9.52 billion in 2021, driven by the increasing geriatric population and road accidents. Aided by the increasing lifestyle diseases, and risi...
NEWSLETTER